Zobrazeno 1 - 10
of 320
pro vyhledávání: '"Michael J. Pishvaian"'
Autor:
Neel D. Trivedi, Samantha Armstrong, Hongkun Wang, Marion Hartley, John Deeken, A. Ruth He, Deepa Subramaniam, Heather Melville, Chris Albanese, John L. Marshall, Jimmy Hwang, Michael J. Pishvaian
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 1944-1954 (2021)
ABSTRACT Background Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors are combined with cytotoxic chemotherapy. We performed a Phase I assessment of the combina
Externí odkaz:
https://doaj.org/article/f18add4e627d4d0ea61548ba2ddd4099
Autor:
Ezra E. W. Cohen, Michael J. Pishvaian, Dale R. Shepard, Ding Wang, Jared Weiss, Melissa L. Johnson, Christine H. Chung, Ying Chen, Bo Huang, Craig B. Davis, Francesca Toffalorio, Aron Thall, Steven F. Powell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 with agonist antibodi
Externí odkaz:
https://doaj.org/article/e6f6835c562540da97a0a035be2449fc
Autor:
Michael Smith, Aung Naing, Todd Bauer, Kyriakos P Papadopoulos, Osama Rahma, Elena Garralda, Glenn J Hanna, Michael J Pishvaian, Xuejun Chen, Sven Gogov, Omar Saavedra, Howard Kallender, LuLu Cheng, Emil Kuriakose
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.Methods and analysis In this non-randomised, o
Externí odkaz:
https://doaj.org/article/2ecbc50a50ee44ec83f8a17ad29ac490
Autor:
Heinz-Josef Lenz, Wei-Ping Lee, Ruey-Kuen Hsieh, Michael J. Pishvaian, Dina Sakaeva, Susan G. Urba, Oleg Gladkov, Sun-Young Rha, Tomomi Kaneko, Colleen Briner, Kevin M. Koch, Yasir M. Nagarwala, Peter M. Wilson, Wu Zhang, Dongyun Yang, Melissa J. LaBonte
Changes in tumor size relative to Week 6 lapatinib concentrations (ng/mL).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f613916f461d28eef467cc0253b6926
https://doi.org/10.1158/1535-7163.22503798
https://doi.org/10.1158/1535-7163.22503798
Autor:
Jonathan R. Brody, Michael J. Pishvaian, Talia Golan, Charles J. Yeo, Wei Jiang, James Posey, Liang Xu, Gloria H. Su, Chunhua Xi, Austin Goetz, Alex Haber, Samantha Z. Brown, Aditi Jain, Christopher W. Schultz, Teena Dhir
Supplemental figure 7: (A) GR50 comparison of Mia PaCa2 (top) or Panc-1 (bottom) parental cells, and their respective "chronic" abemaciclib therapy cells once treated with abemaciclib. These "chronic" abemaciclib therapy cells were then liberated fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::442d015f699cca568ef2d5af6443468c
https://doi.org/10.1158/1541-7786.22516441
https://doi.org/10.1158/1541-7786.22516441
Autor:
Priscilla A. Furth, Donald D. Muccio, Clinton J. Grubbs, Michael J. Pishvaian, Bhaskar V.S. Kallakury, Edgar S. Díaz-Cruz, M. Carla Cabrera
PDF file - 643K, Relative expression levels of Cdk1, Rbl1 and Cdc25a in 4- and 7-month-old mice before and after TAg down-regulation by doxycycline treatment for 14 days and in conjunction with treatment with PD0332991 for 10 days, UAB30 for 14 days,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18fab4c28919e1a5c101a4fde8c129ac
https://doi.org/10.1158/1940-6207.22525134
https://doi.org/10.1158/1940-6207.22525134
Autor:
Jonathan R. Brody, Michael J. Pishvaian, Talia Golan, Charles J. Yeo, Wei Jiang, James Posey, Liang Xu, Gloria H. Su, Chunhua Xi, Austin Goetz, Alex Haber, Samantha Z. Brown, Aditi Jain, Christopher W. Schultz, Teena Dhir
Supplemental figure 3: (A) Quantification of total β-galactosidase positive counts over total cells present, for H2O2 treated cells and no treatment cells. Cells were either treated constantly with H2O2 at 10µM or 100µM, or two hours prior to coll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::356691b5e52a35729ff0754229a83ffa
https://doi.org/10.1158/1541-7786.22516453.v1
https://doi.org/10.1158/1541-7786.22516453.v1
Autor:
Sunnie S. Kim, Jia Zeng, Richard M. Goldberg, Philip A. Philip, Mohamed Salem, W. Michael Korn, Heinz-Josef Lenz, Anthony F. Shields, Ari M. VanderWalde, John L. Marshall, Jimmy J. Hwang, Yasmine Baca, Michael J. Pishvaian, Axel Grothey, Joanne Xiu, Michael Cerniglia
Supplemental Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20cad4ec26e1e4a56d1246bbd8e74fc2
https://doi.org/10.1158/1535-7163.22522530.v1
https://doi.org/10.1158/1535-7163.22522530.v1
Autor:
Jonathan R. Brody, Michael J. Pishvaian, Talia Golan, Charles J. Yeo, Wei Jiang, James Posey, Liang Xu, Gloria H. Su, Chunhua Xi, Austin Goetz, Alex Haber, Samantha Z. Brown, Aditi Jain, Christopher W. Schultz, Teena Dhir
Supplemental figure 5: (A) Loewe synergy plots for Mia PaCa2 and Panc-1 cells treated with abemaciclib with 5-florouracil (5-FU) or irinotecan. (B) Percent viability for various combination therapies, in Mia PaCa2 and Panc-1 cells, after treatment wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::073e24c9442fe56916be89c1ed3fb798
https://doi.org/10.1158/1541-7786.22516447.v1
https://doi.org/10.1158/1541-7786.22516447.v1
Autor:
Heinz-Josef Lenz, Wei-Ping Lee, Ruey-Kuen Hsieh, Michael J. Pishvaian, Dina Sakaeva, Susan G. Urba, Oleg Gladkov, Sun-Young Rha, Tomomi Kaneko, Colleen Briner, Kevin M. Koch, Yasir M. Nagarwala, Peter M. Wilson, Wu Zhang, Dongyun Yang, Melissa J. LaBonte
Figure Legends for Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dc97f021857e36c6fff49c513b7604f
https://doi.org/10.1158/1535-7163.22503795.v1
https://doi.org/10.1158/1535-7163.22503795.v1